GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

Biotech has been hard hit, as one might expect, leaving many names in bargain territory. Learn why there are opportunities ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

A risk to GSK is legal action arising from the alleged ill effects of one of its products. Lawsuits against ... to help you protect and grow your portfolio. We have taken reasonable steps to ...

Second, the threat of tariffs imposed on the USA’s allies is already causing retaliatory measures, including the potential substitution of American products ... respiratory. GSK is a world leader in ...

Value stocks offer good opportunities for long-term investment in 2025, especially for investors who want stability and ...

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

GSK is a world leader in vaccines and has a broad portfolio targeting diseases such as shingles, meningitis, and influenza. In pharmaceuticals, it develops treatments for conditions including ...